Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review

References

• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. doi:10.1038/s41413-018-0016-9
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
   PubMed Web of Science ®Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res Ther. 2002;4:S265.
   Web of Science ®Google Scholar
• Bustamante M, Garcia-Carbonell R, Whisenant KD, et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19:110. doi:10.1186/s13075-017-1303-3
   PubMed Web of Science ®Google Scholar
• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Chen Z, Volin MV, et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18:433–448.
   PubMed Web of Science ®Google Scholar
• Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010;103:139–146.
   PubMed Web of Science ®Google Scholar
• Mohamed AH, Abdellatif S, El-Noshokaty EH. Serum level of 14-3-3η (Eta) protein as a diagnostic marker for rheumatoid arthritis and potential correlation with disease activity. MOJ Orthop Rheumatol. 2017;7:00280.
   Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8:e60635.
   PubMed Web of Science ®Google Scholar
• Xu K, Ren X, Ju B, et al. Clinical markers combined with HMGB1 polymorphisms to predict efficacy of conventional DMARDs in rheumatoid arthritis patients. Clin Immunol. 2020;221:108592.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Matsubara T, Fukuda K, et al. Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis. Sci Rep Sc. 2020;10:16645. doi:10.1038/s41598-020-73968-3
   PubMed Web of Science ®Google Scholar
• Sunar İ, Ataman Ş. Serum C-reactive protein/albumin ratio in rheumatoid arthritis and its relationship with disease activity, physical function, and quality of life. Arch Rheumatol. 2020;35:247–253.
   PubMed Web of Science ®Google Scholar
• He Y, Tang J, Wu B, et al. Correlation between albumin to fibrinogen ratio, C-reactive protein to albumin ratio and Th17 cells in patients with rheumatoid arthritis. Clin Chim Acta. 2020;500:149–154.
   PubMed Web of Science ®Google Scholar
• Wang J, Xi H, Zhang K, et al. Circulating C-reactive protein to prealbumin ratio and prealbumin to fibrinogen ratio are two promising inflammatory markers associated with disease activity in rheumatoid arthritis. Clin Lab. 2020;66. doi:10.7754/Clin.Lab.2019.190833.
   Web of Science ®Google Scholar
• Vanier A, Smolen J, Allaart C, et al. An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. Rheumatology (Oxford). 2020;59:1842–1852.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Soen S, Ishiguro N, et al. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: analysis of data from the DRIVE and DESIRABLE studies. Mod Rheumatol. 2020;31:34–41.
   PubMed Web of Science ®Google Scholar
• Carrier N, De Brum-Fernandes AJ, Liang P, et al. Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers. RMD Open. 2020;6:e001191.
   PubMed Web of Science ®Google Scholar
• Ziegelasch M, Boman A, Martinsson K, et al. Anti-cyclic citrullinated peptide antibodies are associated with radiographic damage but not disease activity in early rheumatoid arthritis diagnosed in 2006–2011. Scand J Rheumatol. 2020;49:434–442.
   PubMed Web of Science ®Google Scholar
• Tan YK, Li H, Allen JC, et al. Anti‐cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound‐detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity. Int J Rheum Dis. 2020;23:1337–1343.
   PubMed Web of Science ®Google Scholar
• Yuan X, Cui S, Liu Y, et al. Analysis of serum rheumatoid factors in patients with rheumatoid arthritis in Han, Tibetan and Hui nationalities in Qinghai. Int Immunopharmacol. 2020;83:106380.
   PubMed Web of Science ®Google Scholar
• Cho J, Pyo JY, Fadriquela A, et al. Comparison of the analytical and clinical performances of four anti-cyclic citrullinated peptide antibody assays for diagnosing rheumatoid arthritis. Clin Rheumatol Clinical. 2020;40:565–573.
   PubMed Web of Science ®Google Scholar
• Pongratz G, Frieser R, Brinks R, et al. Association between autoantibody level and disease activity in rheumatoid arthritis is dependent on baseline inflammation. Clin Exp Rheumatol. 2020;38:691–698.
   PubMed Web of Science ®Google Scholar
• Al-Qtaitat A, Mwafi N, Albtoosh A, et al. A new tool for early diagnosis of rheumatoid arthritis using a combined biomarkers; synovial MAGE-1 mRNA and serum anti-CCP and R. Pan Afr Med J. 2020;36:270.
   PubMed Web of Science ®Google Scholar
• Hu XL, Gu Y, Wu DL, et al. A nomogram to predict recurrence of RA patients in clinical remission within one year. Eur Rev Med Pharmacol Sci. 2020;24:9797–9806.
   PubMed Web of Science ®Google Scholar
• Sun Y, Hong L, Gao C. The association among 14-3-3η protein, inflammation, bone remodeling and osteoporosis in patients with rheumatoid arthritis. Pak J Med Sci. 2020;36:872–876.
   PubMed Web of Science ®Google Scholar
• Tu J, Chen X, Dai M, et al. Serum levels of 14-3-3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients. ExpTher Med. 2020;20:754–761.
   PubMed Web of Science ®Google Scholar
• Hu T, Liu Y, Tan L, et al. Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. Br J Biomed Sci. 2020;78:67–71.
   PubMed Web of Science ®Google Scholar
• Luedders BA, Johnson TM, Sayles H, et al. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. Semin Arthritis Rheum. 2020;50:1058–1063.
   PubMed Web of Science ®Google Scholar
• Baker JF, Curtis JR, Chernoff D, et al. Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. Clin Rheumatol. 2020;40:2419–2426.
   PubMed Web of Science ®Google Scholar
• Razmjou AA, Brook J, Elashoff D, et al. Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. BMC Rheumatol. 2020;4:55.
   PubMedGoogle Scholar
• Jurgens MS, Safy-Khan M, De Hair MJH, et al. The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. Arthritis Res Ther. 2020;22:205. doi:10.1186/s13075-020-02293-x
   PubMed Web of Science ®Google Scholar
• Mhy M, Defranoux N, Li W, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22:158. doi:10.1186/s13075-020-02240-w
   PubMed Web of Science ®Google Scholar
• Lu CH, Chen LF, Huang YM, et al. Anti-cyclic citrullinated peptide antibodies correlate to ultrasound synovitis in rheumatoid arthritis better than c-reactive protein. J Clin Rheumatol. 2021;27:e412–e17.
   PubMed Web of Science ®Google Scholar
• Yasmin R, Sarker H. Anti-CCP antibody in rheumatoid arthritis patients and its relation with severity of the disease. BIRDEM Med J. 2021;12:36–40.
   Google Scholar
• Hossain M, Habib DMA, Asraf DMM. Comparative socio-demographic and disease related characteristics between anti-CCP positive and negative rheumatoid arthritis patients. Sch J App Med Sci. 2021;4:612–620.
   Google Scholar
• Chen Z, Fang W, Qin Y, et al. Citrullinated antigens with multiple citrulline similar motif in the diagnosis of rheumatoid arthritis: a preliminary single-center study. J Immunol Res. 2021;2021:1891519.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ghosh SD, Chandra A, et al. A comparative assessment of the diagnostic value of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis in a tertiary care hospital. J Indian Med Assoc. 2021;119:35–37.
   Google Scholar
• Rajalingham S, Shaharir SS, Mahadzir H. AB0155 comparative analyses of serological biomarkers and disease characteristics between elderly onset rheumatoid arthritis (EORA) and younger onset rheumatoid arthritis (YORA). Ann Rheum Dis. 2021;80:1105.
   PubMed Web of Science ®Google Scholar
• Versteeg GA, Steunebrink L, Vonkeman HE, et al. Early radiological progression remains associated with long-term joint damage in real-world rheumatoid arthritis patients treated to the target of remission. Scand J Rheumatol. 2021;21:1–10.
   Google Scholar
• Zahir Hussain WH, Jubber A, Moorthy A. Are there any ethnic differences in the response to baricitinib for the treatment of rheumatoid arthritis? Cureus. 2021;13:e20024.
   PubMed Web of Science ®Google Scholar
• Santos-Moreno P, Martinez S, Ibatá L, et al. Certolizumab can also be effective in monotherapy for the treatment of rheumatoid arthritis patients. Biologics. 2021;15:433–440.
   PubMed Web of Science ®Google Scholar
• Kao CM, Yen TH, Lai KL, et al. Association between a decrease in anti-cyclic citrullinated protein levels with the concomitant use of disease-modifying antirheumatic drugs in rheumatoid arthritis patients treated with tumor necrosis factor inhibitors or Abatacept. Formosan J Rheumatol. 2021;35:47–56.
   Google Scholar
• Hussin DAAH, Shaat RM, Metwally SS, et al. The significance of serum 14-3-3η level in rheumatoid arthritis patients. Clin Rheumatol. 2021;40:2193–2202.
   PubMed Web of Science ®Google Scholar
• Tashpulatova MM, Nabiyeva DA, Djurayeva ER, et al. Diagnostic significance of 14-3-3η (Eta) protein and MRI of joints in early stage of rheumatoid arthritis. Am J Med Med Sci. 2021;11:165–169.
   Google Scholar
• Curtis JR, Weinblatt ME, Shadick NA, et al. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Res Ther. 2021;23:1. https://doi.org/10.1186/s13075-020-02389-4
   PubMed Web of Science ®Google Scholar
• Yang WM, Zhang WH, Ying HQ, et al. Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: albumin to fibrinogen ratio and C-reactive protein to albumin ratio. Int Immunopharmacol. 2018;62:293–298.
   PubMed Web of Science ®Google Scholar
• Garip Y, Eser F, Bodur H. Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status. Rheumatol Int. 2011;31:769–772.
   PubMed Web of Science ®Google Scholar
• Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: health assessment questionnaire disability index (HAQ), modified health assessment questionnaire (MHAQ), multidimensional health assessment questionnaire (MDHAQ), health assessment questionnaire II (HAQ-II), improved health assessment questionnaire (improved HAQ), and rheumatoid arthritis quality of life (RAQoL). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S4–13.
   PubMed Web of Science ®Google Scholar
• Zou Y-X, Qiao J, Zhu H-Y, et al. Albumin-to-fibrinogen ratio as an independent prognostic parameter in untreated chronic lymphocytic leukemia: a retrospective study of 191 cases. Cancer Res Treat. 2019;51(2):664–671.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishizuka M, Suzuki T, et al. The value of the C-reactive protein-to-albumin ratio is useful for predicting survival of patients with Child-Pugh class a undergoing liver resection for hepatocellular carcinoma. World J Surg. 2018;42:2218–2226.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen QG, Li SQ, et al. Preoperative fibrinogen to prealbumin ratio as a novel predictor for clinical outcome of hepatocellular carcinoma. Future Oncol. 2019;15:13–22.
   PubMed Web of Science ®Google Scholar
• Xu WY, Zhang HH, Xiong JP, et al. Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. World J Gastroenterol. 2018;24:3281–3292.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009;48:1114–1121.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015;74:1102–1109.
   PubMed Web of Science ®Google Scholar
• Mohammed Ali DM, Al-Fadhel SZ, Al-Ghuraibawi NHA, et al. Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis. Reumatologia. 2020;58:67–75.
   PubMedGoogle Scholar
• Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2016;75:356–361.
   PubMed Web of Science ®Google Scholar
• Yang J, Shao Q, Wu J. Correlation between high-frequency ultrasonography of patients with early rheumatoid arthritis and anti-CCP antibody. Medicine (Baltimore). 2019;98:e14083.
   PubMed Web of Science ®Google Scholar
• Serdaroflu M, Cakirbay H, Deger O, et al. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int. 2008;28:965–970.
   PubMed Web of Science ®Google Scholar
• Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology. 2003;42:677–680.
   PubMed Web of Science ®Google Scholar
• Binesh F, Salehabadi HS, Behniafard N, et al. A comprehensive assessment of the diagnostic value of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis. J Clin Exp Pathol. 2014;4:158.
   Google Scholar
• Aflaky E, Shenavandeh S, Ashraf MJ. A comparison of performance of anti-cyclic citrullinated peptide 2 and citrullinated protein antibodies in the diagnosis of rheumatoid arthritis in Iranian patients. Rheumatol Int. 2010;30:461–466.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016;45:519–532.
   PubMed Web of Science ®Google Scholar
• Du Y, Liu X, Guo JP, et al. Association between PADI4 gene polymorphisms and anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis in a large Chinese Han cohort. Clin Exp Rheumatol. 2014;32:377–382.
   PubMed Web of Science ®Google Scholar
• Alten R, Nüßlein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 2017;3:e000345.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Inui T, et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res Ther. 2017;19:194.
   PubMed Web of Science ®Google Scholar
• Gong X, Xu SQ, Wu Y, et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017;36:2581–2587.
   PubMed Web of Science ®Google Scholar
• Zeng T, Tan L. 14-3-3η protein: a promising biomarker for rheumatoid arthritis. Biomark Med. 2018;12:917–925.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Bolce RJ, Wallman JK, et al. Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial J. Rheumatol. 2019;46:555–563.
   Web of Science ®Google Scholar
• Curtis JR, Yang S, Chen L, et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2015;67:1345–1353.
   PubMed Web of Science ®Google Scholar
• Johnson TM, Register KA, Schmidt CM, et al. Correlation of the multi-biomarker disease activity score with rheumatoid arthritis disease activity measures: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2019;71:1459–1472.
   PubMed Web of Science ®Google Scholar
• Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75:1637–1644.
   PubMed Web of Science ®Google Scholar
• Brahe CH, Østergaard M, Johansen JS, et al. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scand J Rheumatol. 2019;48:9–16.
   PubMed Web of Science ®Google Scholar
• Markusse IM, Dirven L, van den Broek M, et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the best study. J Rheumatol. 2014;41:2114–2119.
   PubMed Web of Science ®Google Scholar
• Li W, Sasso EH, van der Helm-van Mil AH, et al. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology. 2016;55:357–366.
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013;52:839–846.
   PubMed Web of Science ®Google Scholar